The Malaysian Reserve

Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTSAbstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released.The study was led by Prof Louise Emmett at ...

Clarity Pharmaceuticals: Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial

HIGHLIGHTS Abstract outlining key findings from the Co-PSMA Investigator-Initiated Trial (IIT) has been released. The study was led by Prof Louise Emmett at St Vincent's ...
MyChesCo on MSN

Medicus Pharma receives FDA clearance to begin Phase 2b Teverelix study

PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has received “study may proceed” clearance from the U.S. Food and Drug Administration to initiate a Phase 2b dose-optimization trial ...